. 2019 May 1;9(4):e025537. doi: 10.1136/bmjopen-2018-025537

Table 1.

Baseline characteristics of the studies included in meta-analysis

Study /year /reference	Study location	Sample size		Intervention		LVEF,%		Age, years		Follow-up duration	Primary outcome
Study /year /reference	Study location	Tolvaptan	Control	Tolvaptan	Control	Tolvaptan	Control	Tolvaptan	Control	Follow-up duration	Primary outcome
Jujo et al 2016²⁵	Japan	30	30	Tolvaptan 7.5 mg/day + carperitide	Furosemide + carperitide	45(33,55)^*	46(37,60)*	79±11	79±11	5 days	WRF, changes in urine volume, serum creatinine, BUN, BNP and catecholamines
Tamaki et al 2017²⁶	Japan	26	24	Tolvaptan 7.5 or 15 mg/day + diuretic	Diuretic	60.7±10.0	59.7±7.5	79±7	75±10	48 hours	WRF, changes in serum creatinine, BUN, body weight, urine volume, secrum sodium and eGFR
Konstam et al 2017²²	USA	122	128	Tolvaptan 30 mg/day + diuretic	Placebo + diuretic	35±16	33±17	70±11	67±13	7 days	WRF, changes in body weight, dyspnoea relief, eGFR and serum creatinine, 30 day mortality or re-hospitalisation
Felker et al 2017²³	USA	129	128	Tolvaptan 30 mg/day + loop diuretic	Placebo + loop diuretic	34±17	32±17	66±13	63±16	48 hours	WRF, changes in body weight, serum sodium, dyspnoea relief and urine volume, worsening HF and 30 day mortality
Shanmugam et al 2016²⁴	India	25	26	Tolvaptan 15 mg/day + diuretic	Diuretic	31.9±12.2	29.2±8.7	58.9±12.1	57±12	5 days	Changes in plasma sodium and dyspnoea relief, adverse effects
Matsue et al 2016²⁰	Japan	108	109	Tolvaptan 15 mg/day + conventional therapy	Conventional therapy	45.4±18.1	46.8±16.4	72.99±8.9	72.95±10.24	636 days	WRF, changes in body weight, serum sodium, dyspnoea relief, BNP and urine volume, in-hospital death, adverse effects
Kimura et al 2016¹²	Japan	26	26	Tolvaptan 15 mg/day + furosemide 20 mg	Furosemide	47.54±16.75	56.73±11.52	80.54±12.15	86.15±4.95	7 days	WRF, changes in mean creatinine clearance and eGFR, adverse effects

Data are given as the mean ±SD deviation

*Data presented as median with IQR.

BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; WRF, worsening renal function.